GeneDx announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry. The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health?s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment. GeneDx's rare disease data set is recognized for its depth and accuracy, making it a valuable resource for biopharmaceutical companies seeking to identify novel therapeutic targets and optimize clinical trial design.

As a MapEnhance specialty partner, GeneDx?s rich repository of de-identified genetic data will be accessible through Komodo?s end-to-end platform, to help companies unlock deeper insights into genetically based disease and accelerate new breakthroughs and treatments for patients. GeneDx is continuing to showcase its value to biopharma companies through its participation in the World Orphan Drug Congress meeting in Boston, April 23-25th. At the meeting, GeneDx will present a panel ?Enabling precision medicine as the standard of care,?

looking at different perspectives of the lab, biopharma and a parent perspective, on how genomic information can advance precision medicine. GeneDx offers customized solutions for biopharma partners across all stages of the drug development cycle ? from early research & development to clinical trial recruitment and more.

Find: Leverage GeneDx?s unmatched dataset to find clinicians and patients; Explore: Use clinicogenomic insights to inform the drug discovery process and cohort builders to inform market insights and Partner: Joint programs aimed at increasing access, accelerating diagnosis, and finding patients.